ScandiBio Featured on Life Science Sweden’s 2026 Phase III Watchlist
Sweden’s life science sector is entering a decisive phase. A recent overview from Life Science Sweden highlights that a growing number of Swedish life science companies…
-
-
Meet our CEO Olof Nord at the upcoming Bioscience event
Organized by Life Science Sweden the event will take place at GoCo Health Innovation City in Gothenburg on March 26, 2026. We are excited to participate…
-
First 100 Patients Enrolled in Phase 3 Trial of ScandiBio Therapeutics AI-developed Drug for Alzheimer’s Disease
Stockholm, 4 December, 2025 – ScandiBio Therapeutics AB today announced that the first 100 patients have been recruited to the multi-centre, phase 3 human clinical trial…
-
ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive impairments that are significant enough…
-
Metabolic Activators Therapy Improve Liver Fat in NAFLD Patients
A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduction in liver fat when receiving the combination of…
-
Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Parkinson’s disease patients
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The results: Combined Metabolic Activators Improve Cognitive Functions without Altering…
-
Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Alzheimer’s disease patients
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The study: Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s…
-
The results of a phase II and III clinical trials about the treatment of COVID-19 patients with CMAs have been published at Advanced Science
The results of a Phase II and III studies have been published in the journal Advanced Science. COVID-19 is associated with mitochondrial dysfunction and metabolic abnormalities,…
-
The results of a phase I study of CMCS have been published
The results of a Phase I study have been published in the journal Molecular Systems Biology describing the kinetics of the Combined Metabolic Cofactor Supplementation (CMCS)…
-
An article has been published how to address the heterogeneity in liver diseases with AI-based genome metabolic modeling
An article has been published in Briefings in Bioinformatics about the heterogeneity in liver diseases. The abnormalities in human metabolism have been implicated in the progression…
